Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01073436 · ClinicalTrials.gov registry record
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- 7
- Enrollment target
NCT01073436: Clinical Trial study, sponsored by University of Michigan Rogel Cancer Center.
NCT01073436 is a clinical trial that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01073436 was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission, are able to discontinue therapy and maintain a durable remission. Relapse-free survival (RFS) rate at 1 year after discontinuation of TKI will be the measurement of this objective.
Primary Outcome
Relapse-free survival (RFS) rate at 1 year after discontinuation of TKI will be the measurement of this objective.
Interventions
- OTHER Discontinuation of therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-11 |
Why NCT01073436 stopped before completion
NCT01073436 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Discontinuation of therapy is the first listed.
NCT01073436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01073436 about?
NCT01073436 is a clinical study titled "Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha". To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecula...
What is the current status of trial NCT01073436?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2009-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01073436?
The interventions under investigation include: Discontinuation of therapy (OTHER).
Who is sponsoring clinical trial NCT01073436?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia